12 Best Mid-Cap Stocks with Huge Upside Potential

Page 8 of 12

5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Analyst Upside: 45.02%

Market Capitalization: $6.80 billion

Number of Hedge Fund Holders: 45

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) ranks among the best mid-cap stocks with huge upside potential. On August 22, following the FDA approval of the company’s treatment for hereditary angioedema (HAE), Piper Sandler maintained its Overweight rating on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and raised its price target from $62 to $65.

Dawnzera (donidalorsen), Ionis’ second independent product approval and launch, was approved by the FDA for use in adult and pediatric HAE patients aged 12 and above.

In this context, the firm emphasized Ionis’s skilled sales team in immunology and allergy, with a focus on the HAE market. Given that HAE is largely seen as a market where patients switch between therapies, this expertise might prove beneficial.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) produces medications for serious medical conditions, with a specific emphasis on cardiovascular and neurological disorders.

Page 8 of 12